In Depth Review of COVID-19 Effect on CVS

Corona virus disease 2019 (covid-19) is global pandemic affecting 185 countries and > 30,00,000 patient worldwide as of April 28,2020COVID-19 is caused by severe acute respiratory syndrome corona virus. Which invades cells through the angiotensin – convertingenzyme 2 receptor. Among patient with COVID-19, there is a high prevalence of cardiovascular disease and > 7% of patientsexperience myocardial injury from the infection (22% of critically ill patients). Although angiotensin – converting enzyme 2 serves asthe portal for infection, the role of angiotensin – converting enzyme inhibitor or angiotensin receptor blockers requires furtherinvestigation. COVID-19 poses a challenge for heart transplantation, affecting donor selection. Immunosuppression and posttransplant management. Primary cardiac manifestation includes acute myocarditis, myocardial infarction, arrhythmia and abnormalclotting. The disease does not discrimate but increasing age & the presence of comorbidities are associated with severe form of thedisease and poor outcomes. While our knowledge of COVID-19 continues to rapidly expend, this review highlights recent advances inour understanding of the interaction between COVID-19 & the cardiovascular system. Management of acute COVID-19 cardiovascularsyndrome should involve a multidisciplinary team including intensive care specialists, infectious disease specialists and cardiologists.Clinical and diagnostic details of cardiovascular involvement in these patients a mostly limited to biochemical markers. Cardiovasculardrugs the cardiac effect of therapeutic agent on the illness continue to be under investigation with an increasing number of patientsnewer promising therapies and ongoing clinical trials the exact mechanisms & extent to which this risk. Factors contribute tooutcomes will be clearer in the future.